Loading...

Galectin Therapeutics

DB:PHPN
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PHPN
DB
$196M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The last earnings update was 44 days ago. More info.


Add to Portfolio Compare Print
  • Galectin Therapeutics has significant price volatility in the past 3 months.
PHPN Share Price and Events
7 Day Returns
-10%
DB:PHPN
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
29.1%
DB:PHPN
-10.6%
DE Biotechs
-6.2%
DE Market
PHPN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Galectin Therapeutics (PHPN) -10% -13.7% -10.2% 29.1% 173.8% -55.1%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • PHPN outperformed the Biotechs industry which returned -10.6% over the past year.
  • PHPN outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
PHPN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Galectin Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Galectin Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Galectin Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Galectin Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €3.77.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Galectin Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Galectin Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PHPN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.38
NasdaqCM:GALT Share Price ** NasdaqCM (2019-04-18) in USD $4.3
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Galectin Therapeutics.

DB:PHPN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:GALT Share Price ÷ EPS (both in USD)

= 4.3 ÷ -0.38

-11.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Galectin Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Galectin Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Galectin Therapeutics's expected growth come at a high price?
Raw Data
DB:PHPN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-16.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Galectin Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Galectin Therapeutics's assets?
Raw Data
DB:PHPN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.05
NasdaqCM:GALT Share Price * NasdaqCM (2019-04-18) in USD $4.3
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:PHPN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:GALT Share Price ÷ Book Value per Share (both in USD)

= 4.3 ÷ -0.05

-86.66x

* Primary Listing of Galectin Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Galectin Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Examine Galectin Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Galectin Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Galectin Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Galectin Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Galectin Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-16.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Galectin Therapeutics expected to grow at an attractive rate?
  • Unable to compare Galectin Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Galectin Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Galectin Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:PHPN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PHPN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -16.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PHPN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PHPN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 32 -93 -41 2
2022-12-31 0 -63 -49 2
2021-12-31 0 -39 -35 2
2020-12-31 0 -25 -30 2
2019-12-31 0 -15 -29 2
DB:PHPN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -10 -15
2018-09-30 -12 -14
2018-06-30 -14 -16
2018-03-31 -16 -17
2017-12-31 -16 -17
2017-09-30 -17 -20
2017-06-30 -17 -20
2017-03-31 -17 -21
2016-12-31 -16 -22
2016-09-30 -16 -22
2016-06-30 -18 -24
2016-03-31 -16 -23

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Galectin Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Galectin Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PHPN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Galectin Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PHPN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.73 0.11 -1.57 2.00
2022-12-31 -0.87 -0.53 -1.21 2.00
2021-12-31 -0.62 -0.45 -0.78 2.00
2020-12-31 -0.55 -0.52 -0.58 2.00
2019-12-31 -0.58 -0.42 -0.74 2.00
DB:PHPN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.38
2018-09-30 -0.37
2018-06-30 -0.43
2018-03-31 -0.46
2017-12-31 -0.49
2017-09-30 -0.59
2017-06-30 -0.61
2017-03-31 -0.67
2016-12-31 -0.76
2016-09-30 -0.79
2016-06-30 -0.89
2016-03-31 -0.90

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Galectin Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Galectin Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Galectin Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Galectin Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Galectin Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Galectin Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Galectin Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Galectin Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Galectin Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Galectin Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PHPN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -15.05 7.13 6.47
2018-09-30 -14.49 6.71 6.28
2018-06-30 -16.10 6.45 8.28
2018-03-31 -16.80 5.23 10.25
2017-12-31 -17.47 4.53 11.72
2017-09-30 -19.55 5.20 14.15
2017-06-30 -19.53 5.54 13.94
2017-03-31 -20.55 5.77 14.72
2016-12-31 -22.35 6.16 15.33
2016-09-30 -22.45 5.88 14.81
2016-06-30 -23.96 6.07 15.98
2016-03-31 -23.06 6.82 14.36
2015-12-31 -21.12 6.97 13.11
2015-09-30 -20.13 6.70 12.28
2015-06-30 -17.83 6.76 9.80
2015-03-31 -16.63 6.49 8.79
2014-12-31 -16.96 6.86 8.43
2014-09-30 -16.10 5.83 7.74
2014-06-30 -15.97 6.69 6.95
2014-03-31 -23.88 6.10 6.71
2013-12-31 -21.95 5.49 5.69
2013-09-30 -21.54 6.39 5.30
2013-06-30 -20.81 5.52 5.51
2013-03-31 -12.15 5.78 5.38
2012-12-31 -10.88 5.37 4.53
2012-09-30 -11.89 6.34 4.39
2012-06-30 -11.25 6.23 3.63

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Galectin Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Galectin Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Galectin Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Galectin Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Galectin Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Galectin Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Galectin Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Galectin Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Galectin Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Galectin Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Galectin Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Galectin Therapeutics Company Filings, last reported 3 months ago.

DB:PHPN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6.90 0.00 8.25
2018-09-30 8.97 0.00 10.14
2018-06-30 9.78 0.00 10.50
2018-03-31 2.65 0.00 3.99
2017-12-31 1.19 0.00 3.05
2017-09-30 2.67 0.00 6.96
2017-06-30 5.82 0.00 9.13
2017-03-31 9.64 0.00 13.64
2016-12-31 12.02 0.00 15.36
2016-09-30 12.03 0.00 16.06
2016-06-30 14.61 0.00 18.00
2016-03-31 19.54 0.00 22.36
2015-12-31 25.05 0.00 25.85
2015-09-30 19.79 0.00 21.32
2015-06-30 24.77 0.00 26.36
2015-03-31 28.68 0.00 29.35
2014-12-31 27.97 0.00 29.13
2014-09-30 29.94 0.00 31.20
2014-06-30 32.45 0.00 34.42
2014-03-31 34.96 0.00 36.59
2013-12-31 8.23 0.00 10.49
2013-09-30 8.17 0.00 9.72
2013-06-30 3.73 0.00 5.10
2013-03-31 5.72 0.00 7.02
2012-12-31 7.92 0.00 9.36
2012-09-30 9.75 0.00 11.06
2012-06-30 11.54 0.00 13.13
  • Galectin Therapeutics has no debt.
  • Galectin Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Galectin Therapeutics has less than a year of cash runway based on current free cash flow.
  • Galectin Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.4% each year.
X
Financial health checks
We assess Galectin Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Galectin Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Galectin Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Galectin Therapeutics dividends.
If you bought €2,000 of Galectin Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Galectin Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Galectin Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PHPN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PHPN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Galectin Therapeutics has not reported any payouts.
  • Unable to verify if Galectin Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Galectin Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Galectin Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Galectin Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Galectin Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Galectin Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Galectin Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Harold Shlevin
COMPENSATION $1,730,815
AGE 68
TENURE AS CEO 0.8 years
CEO Bio

Dr. Harold H. Shlevin, Ph.D., has been President and Chief Executive Officer at Galectin Therapeutics, Inc. since July 06, 2018. He was Chief Operating Officer and Corporate Secretary of Galectin Therapeutics, Inc., from October 1, 2012 to July 06, 2018. Prior to his work at Galectin, Dr. Shlevin served Georgia Institute of Technology’s Advanced Technology Development Center (ATDC) as manager of bioscience partnering and commercialization efforts. Dr. Shlevin was a Principal and Head of Bioscience Commercialization at Advanced Technology Development Center at Georgia Institute of Technology. He is a Biosciences Startup Catalyst at Advanced Technology Development Center. He is a 30-year bioscience-industry executive with broad senior management experience in medical devices, pharmaceuticals, diagnostics and vaccines. From October 2008 to November 2009, he served as Head of Operations and Commercial Development for Altea Therapeutics Corporation. He has founded two startup companies. Dr. Shlevin served as Vice President of Product Commercial Development at Altea Therapeutics Corporation since May 2009. From July 2006 to September 2008, Dr. Shlevin served as the President and Chief Executive Officer of Tikvah Therapeutics Inc. He served as the Chief Executive Officer and President of Abbott Products, Inc. (also known as Solvay Pharmaceuticals Inc.) from May 2000 to January 2006. He served as Senior Vice President of Business Development and Scientific Affairs of Abbott Products, Inc. since August 1998. His past industry experience includes Senior Executive Positions at Bausch & Lomb Pharmaceuticals, G.D. Searle and Co., Ciba-Geigy Pharmaceuticals (now Novartis) and Ciba Vision and was a Founder of Ciba Vision Opthalmics. Dr. Shlevin served as the Chairman of Unimed Pharmaceuticals Inc. He serves as a Member of the Board of Solvay Draka. He serves as a Member of the Scientific Advisory Board at Clearside BioMedical, Inc. He serves as a Director of Unimed Pharmaceuticals Inc. Dr. Shlevin serves on the Board of Directors of the American Foundation for Suicide Prevention, the Board of Advisors of Morehouse School of Medicine and Board of Directors for the Georgia Biomedical Partnership.He served as a Director at Cardiome Pharma Corp. since October 14, 2004 until June 24, 2016. He served as a Director of Tikvah Therapeutics Inc. and Abbott Products, Inc. He served as an Assistant Professor of Pharmacology and Physiology at the Mayo Graduate School of Medicine, Mayo Foundation and Mayo Clinic. Dr. Shlevin served as a Director of the Pharmaceutical Research & Manufacturers of America, National Pharmaceutical Council. He is a Member of the American Society of Pharmacology and Experimental Therapeutics, the American Physiological Society, the Biophysical Society, the Drug Information Association and the Licensing Executives Society. Dr. Shlevin earned a B.A. degree from Boston University and M.S. and Ph.D. degrees in physiology from the University of Rochester Medical School and postdoctoral fellowship at Mayo Foundation and Mayo Medical School.

CEO Compensation
  • Harold's compensation has increased whilst company is loss making.
  • Harold's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Galectin Therapeutics management team in years:

5.8
Average Tenure
68
Average Age
  • The average tenure for the Galectin Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Harold Shlevin

TITLE
President & CEO
COMPENSATION
$2M
AGE
68
TENURE
0.8 yrs

Jack Callicutt

TITLE
CFO & Secretary
COMPENSATION
$1M
AGE
51
TENURE
5.8 yrs

Robert Tritt

TITLE
General Counsel

Eliezer Zomer

TITLE
Executive Vice President of Manufacturing & Product Development
COMPENSATION
$134K
AGE
71
TENURE
19.3 yrs
Board of Directors Tenure

Average tenure and age of the Galectin Therapeutics board of directors in years:

3
Average Tenure
71
Average Age
  • The average tenure for the Galectin Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Dick Uihlein

TITLE
Chairman
COMPENSATION
$35K
AGE
73
TENURE
0.9 yrs

Kevin Freeman

TITLE
Vice Chairman of the Board
COMPENSATION
$46K
AGE
56
TENURE
1.3 yrs

Jim Czirr

TITLE
Director
COMPENSATION
$39K
AGE
64
TENURE
10.2 yrs

Gil Amelio

TITLE
Director
COMPENSATION
$47K
AGE
75
TENURE
10.2 yrs

Gilbert Omenn

TITLE
Director
COMPENSATION
$45K
AGE
76
TENURE
4.6 yrs

Joel Lewis

TITLE
Director
COMPENSATION
$55K
AGE
48
TENURE
1.3 yrs

Anatole Klyosov

TITLE
Co-founder & Member of the Scientific Board
COMPENSATION
$204K
AGE
71

Marc Rubin

TITLE
Independent Director
COMPENSATION
$51K
AGE
63
TENURE
7.5 yrs

Stephen Shulman

TITLE
Director
COMPENSATION
$41K
AGE
74
TENURE
1.3 yrs

Kevin Mayo

TITLE
Member of the Scientific Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Galectin Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Apr 19 Buy Richard Uihlein Individual 09. Apr 19 09. Apr 19 20,700 €4.28 €88,597
08. Apr 19 Buy Kevin Freeman Individual 05. Apr 19 05. Apr 19 500 €4.22 €2,109
08. Apr 19 Buy Richard Uihlein Individual 05. Apr 19 05. Apr 19 21,000 €4.29 €90,037
08. Apr 19 Buy Joel Lewis Individual 05. Apr 19 05. Apr 19 667 €4.30 €2,866
11. Feb 19 Buy Kevin Freeman Individual 08. Feb 19 08. Feb 19 1,500 €3.78 €5,675
11. Feb 19 Buy Joel Lewis Individual 07. Feb 19 07. Feb 19 1,000 €3.95 €3,949
04. Feb 19 Sell Gilbert Amelio Individual 30. Jan 19 31. Jan 19 -30,000 €4.37 €-130,950
31. Jan 19 Buy Richard Uihlein Individual 28. Jan 19 29. Jan 19 51,500 €4.26 €219,289
30. Jan 19 Buy Joel Lewis Individual 29. Jan 19 29. Jan 19 1,000 €4.21 €4,205
26. Sep 18 Buy Kary Eldred Individual 25. Sep 18 25. Sep 18 2,000 €5.18 €10,364
11. Sep 18 Sell Gilbert Omenn Individual 07. Sep 18 10. Sep 18 -19,370 €5.20 €-100,438
26. Jun 18 Buy Joel Lewis Individual 25. Jun 18 25. Jun 18 1,000 €6.03 €6,035
05. Jun 18 Sell 10x Capital Management, LLC Company 01. Jun 18 04. Jun 18 -50,000 €4.39 €-219,077
X
Management checks
We assess Galectin Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Galectin Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company’s lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Details
Name: Galectin Therapeutics, Inc.
PHPN
Exchange: DB
Founded: 2000
$174,164,021
45,550,226
Website: http://galectintherapeutics.com
Address: Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard,
Suite 240,
Norcross,
Georgia, 30071,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM GALT Common Stock Nasdaq Capital Market US USD 04. Sep 2002
DB PHPN Common Stock Deutsche Boerse AG DE EUR 04. Sep 2002
Number of employees
Current staff
Staff numbers
6
Galectin Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:04
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/07
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.